^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
allogeneic Myeloma GM-CSF Vaccine
i
Other names: allogeneic GVAX myeloma vaccine, allogeneic myeloma vaccine with GM-CSF-secreting K562 cells, GVAX allogeneic myeloma vaccine, MM-GVAX, allogeneic Myeloma GM-CSF Vaccine, allogeneic GM-CSF-secreting multiple myeloma vaccine
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Sidney Kimmel Comprehensive Cancer Center
Drug class:
Immunostimulant, GM-CSF agonist
Related drugs:
3ms
Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission (clinicaltrials.gov)
P2, N=24, Terminated, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N=54 --> 24 | Trial completion date: Dec 2024 --> May 2025 | Active, not recruiting --> Terminated; loss of funding
Enrollment change • Trial completion date • Trial termination
|
lenalidomide • allogeneic Myeloma GM-CSF Vaccine
1year
Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission (clinicaltrials.gov)
P2, N=54, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Sep 2024 --> Dec 2024
Trial completion date
|
lenalidomide • allogeneic Myeloma GM-CSF Vaccine
Share via
